2016
DOI: 10.2217/fca-2015-0009
|View full text |Cite
|
Sign up to set email alerts
|

Improving Lipids With Prescription Icosapent Ethyl After Previous Use of Fish Oil Dietary Supplements

Abstract: Managing dyslipidemia can be challenging in patients with statin intolerance. We describe the lipid effects of icosapent ethyl 4 g/day (high-purity prescription omega-3 eicosapentaenoic acid) in two coronary artery disease patients with statin intolerance who were self-treating with fish oil dietary supplements. After initiating icosapent ethyl, improvements were noted in the first and second patients, respectively, in total cholesterol (-12%; -21%), LDL cholesterol (-3%; -24%), triglycerides (-34%; -16%), non… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2016
2016
2021
2021

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 35 publications
0
2
0
Order By: Relevance
“…The 4-g daily dose decreased LDL-C levels by 6.2% ( p = 0.007) and significantly reduced other lipid parameters compared with a light liquid paraffin placebo, including apolipoprotein B (9.3%; p < 0.0001), very low-density lipoprotein cholesterol (VLDL-C) (24.4%; p < 0.0001), lipoprotein-associated phospholipase A2 (19.0%; p < 0.0001), and high-sensitivity CRP (hsCRP) (22.0%; p = 0.0005) [ 112 ]. One study of IPE in statin-intolerant patients suggested it might be potentially effective in this group of patients [ 113 ].…”
Section: Methodsmentioning
confidence: 99%
“…The 4-g daily dose decreased LDL-C levels by 6.2% ( p = 0.007) and significantly reduced other lipid parameters compared with a light liquid paraffin placebo, including apolipoprotein B (9.3%; p < 0.0001), very low-density lipoprotein cholesterol (VLDL-C) (24.4%; p < 0.0001), lipoprotein-associated phospholipase A2 (19.0%; p < 0.0001), and high-sensitivity CRP (hsCRP) (22.0%; p = 0.0005) [ 112 ]. One study of IPE in statin-intolerant patients suggested it might be potentially effective in this group of patients [ 113 ].…”
Section: Methodsmentioning
confidence: 99%
“…The authors emphasized that the benefits demonstrated in their study should not be transferred to all omega-3 preparations, especially dietary supplements, due to the differences between the composition of supplements compared with the preparation used in their study [24]. The literature also shows that 4 g of icosapent ethyl improves the lipid profile in patients with statin intolerance [25]. Many other experts also emphasize that omega-3 fatty acids (of proven quality) may be particularly beneficial for statin-intolerant patients with obesity, diabetes, or metabolic syndrome in whom elevated LDL cholesterol is accompanied by high levels of triglycerides [26].…”
Section: Polyunsaturated Omega-3 Fatty Acidsmentioning
confidence: 95%